RNA-based Therapies Market to Reach US$213.54 Billion by 2033 at 10.0% CAGR; North America Leads with 45% Share - Key Players: Moderna, Novartis, CRISPR Therapeutics, Genentech, Recordati

The global RNA-based Therapies Market was valued at US$90.56 billion in 2024 and is expected to reach US$213.54 billion by 2033, growing at a CAGR of 10.0% during the forecast period 2025 to 2033. The market is experiencing strong growth as biotechnology and pharmaceutical companies increasingly adopt RNA based technologies to develop advanced therapeutics for a wide range of diseases. RNA based therapies, including messenger RNA vaccines, small interfering RNA treatments, and antisense oligonucleotide therapies, enable targeted regulation of gene expression and offer new approaches for treating complex and previously difficult to manage diseases.

The rising prevalence of genetic disorders, infectious diseases, and chronic conditions is significantly accelerating the demand for RNA based therapeutics. These therapies have gained global attention following the success of mRNA vaccine technologies and are now being widely explored for the treatment of conditions such as Cancer, Cardiovascular Diseases, and Rare Genetic Disorders. In addition, increasing investments in genomic research, advancements in RNA delivery technologies, and expanding clinical research activities are further strengthening the development of innovative RNA based therapeutics, positioning this field as a transformative area in modern precision medicine and next generation drug development.

Download Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/rna-based-therapies-market?sai-v

The RNA based Therapies market is experiencing significant growth as biotechnology and pharmaceutical companies increasingly focus on advanced genetic approaches to treat complex and previously untreatable diseases. RNA based therapies utilize ribonucleic acid molecules to regulate or modify gene expression within cells, enabling targeted treatment at the molecular level. These therapies include technologies such as messenger RNA, small interfering RNA, antisense oligonucleotides, and microRNA based treatments that can silence, replace, or modify disease causing genes. With growing advancements in molecular biology, delivery technologies, and genomic research, RNA based therapeutics are emerging as powerful tools for treating a wide range of conditions including genetic disorders, cancer, infectious diseases, and rare diseases.

For biotechnology companies, pharmaceutical manufacturers, and research institutions, the RNA based therapies ecosystem represents both a transformative medical breakthrough and a significant innovation opportunity. Organizations investing in advanced RNA delivery platforms, lipid nanoparticle technologies, and precision genetic targeting strategies can accelerate drug development and expand treatment possibilities. With continuous progress in genomic medicine, expanding clinical trials, and increasing regulatory support for novel biologic therapies, RNA based therapeutics are expected to play a crucial role in shaping the future of personalized medicine and next generation disease treatment strategies.

Key Developments

✅ February 2026: In the United States and China, SanegeneBio entered a global licensing agreement with Genentech to advance an RNA interference (RNAi) therapy program targeting genetic diseases, strengthening the commercialization potential of next generation gene silencing therapeutics.

✅ January 2026: In Europe and global markets, Recordati partnered with Moderna to develop and commercialize the investigational mRNA therapy mRNA‐3927 for propionic acidemia, a rare metabolic disorder, marking progress toward disease modifying RNA based treatments.

✅ December 2025: In North America, CRISPR Therapeutics formed a strategic collaboration with Sirius Therapeutics to jointly develop small interfering RNA (siRNA) therapies, beginning with a long acting FXI targeting candidate designed to treat thromboembolic disorders.

✅ November 2025: In global markets, pharmaceutical companies expanded clinical pipelines for RNA based therapies targeting oncology, rare genetic disorders, and infectious diseases, with multiple mRNA and RNAi candidates advancing into mid and late stage clinical trials.

✅ October 2025: In the United States, Novartis strengthened its RNA therapeutics pipeline through collaborations focused on RNA interference and antisense oligonucleotide technologies aimed at developing treatments for neurological and rare diseases.

✅ September 2025: In North America and Europe, biotechnology companies accelerated research on next generation RNA platforms including circular RNA and self amplifying RNA technologies designed to improve stability, delivery efficiency, and therapeutic performance of RNA based medicines.

Competitive Landscape and Industry Partnerships
The Short Range Air Surveillance Radar market is characterized by the presence of major global defense contractors and radar technology developers that focus on designing advanced surveillance systems for airspace monitoring and threat detection. Short range air surveillance radars are widely used by military forces and security agencies to detect, track, and identify low altitude airborne threats such as drones, helicopters, and low flying aircraft.

Leading companies operating in the market include Raytheon Technologies (RTX), Lockheed Martin, Northrop Grumman, Thales Group, Saab AB, Leonardo S.p.A., HENSOLDT, Israel Aerospace Industries (ELTA Systems), BAE Systems, and Aselsan A.S., among others. These companies develop advanced radar platforms designed to provide rapid detection, accurate tracking, and reliable surveillance capabilities for both military and homeland security applications.

Market participants are investing in modern radar technologies such as active electronically scanned array systems, digital signal processing, and integrated sensor networks to improve detection accuracy and operational efficiency. These systems are capable of identifying multiple targets simultaneously and operating effectively in complex environments including mountainous terrain, coastal regions, and urban airspaces.

For instance, many modern short range air surveillance radar systems are designed to support air defense networks by providing early warning capabilities and real time situational awareness. They can be deployed for base protection, border surveillance, critical infrastructure monitoring, and counter unmanned aerial system operations.

As global defense forces continue to prioritize airspace security and protection against emerging aerial threats, radar technology manufacturers are expected to expand their research and development activities and introduce advanced surveillance solutions to strengthen national security and defense capabilities.

Purchase Corporate License | Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=rna-based-therapies-market?sai-v

Market Drivers

- Increasing prevalence of genetic and rare diseases is driving demand for targeted RNA-based therapies such as antisense oligonucleotides, small interfering RNA (siRNA), and messenger RNA (mRNA) therapeutics.

- Rapid advancements in RNA technology platforms are enabling the development of novel therapies with improved specificity and efficacy.

- Growing investments from pharmaceutical companies, biotechnology firms, and venture capitalists to accelerate RNA-based drug discovery and development.

- Rising demand for personalized and precision medicine approaches to treat complex conditions, including genetic disorders, cancer, and metabolic diseases.

- Expanding approval of RNA-based drugs and vaccines, increasing patient access to innovative treatments.

- Increasing collaboration between research institutions, technology providers, and pharmaceutical companies to advance RNA therapeutics pipelines.

- Advancements in delivery systems, such as lipid nanoparticles and conjugated oligonucleotides, are improving therapy stability and targeted delivery.

Industry Developments

- Development of next-generation RNA therapeutics, including mRNA vaccines, siRNA treatments, and antisense therapies for rare and genetic diseases.

- Strategic partnerships and collaborations between companies to enhance research, clinical trials, and commercialization of RNA-based drugs.

- Expansion of manufacturing and production capabilities to meet the growing demand for RNA therapeutics globally.

- Increasing focus on improving delivery technologies to enhance cellular uptake, reduce immunogenicity, and increase therapeutic efficiency.

- Rising clinical trials for RNA-based therapies targeting cancer, neuromuscular disorders, metabolic diseases, and infectious diseases.

- Growing adoption of artificial intelligence and computational biology tools to optimize RNA molecule design and accelerate drug development.

Regional Insights

North America 45% share: "Driven by strong presence of leading biotechnology and pharmaceutical companies, advanced clinical research infrastructure, and high investment in RNA-based drug development."

Europe 25% share: "Supported by growing biotechnology research activities, favorable regulatory frameworks, and increasing adoption of precision medicine."

Asia Pacific 22% share: "Fueled by rising healthcare investments, expanding biotech startups, and increasing focus on innovative therapies for genetic and rare diseases."

Latin America 5% share: "Boosted by improving healthcare infrastructure and growing access to novel RNA-based therapies."

Middle East & Africa 3% share: "Driven by increasing awareness about advanced therapeutics and gradual expansion of biotechnology research capabilities."

Speak to Our Analyst and Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/rna-based-therapies-market?sai-v

Key Segments

By Type
Antisense oligonucleotides (ASO) represent a major segment in the RNA therapeutics market as they are designed to bind specific RNA sequences and modulate gene expression, offering targeted treatment for genetic disorders and certain cancers. RNA interference (RNAi) therapies are another significant segment, where small interfering RNAs (siRNAs) are used to silence disease-causing genes, providing precise control over pathological pathways. CRISPR/Cas-based RNA editing systems represent an emerging and highly innovative segment, enabling direct modification of RNA sequences to correct genetic defects or modulate gene expression. mRNA vaccines are a rapidly growing segment, highlighted by their use in infectious disease prevention and immunotherapy, including vaccines for viral infections and emerging pathogens. RNA aptamers represent another specialized segment, offering targeted binding to specific proteins or molecular structures for therapeutic and diagnostic applications. Other types include long non-coding RNA therapeutics and novel RNA-based modalities under development for various medical conditions.

By Indication
Rare genetic diseases represent a key application segment as RNA therapeutics can target specific mutations, offering personalized treatments for conditions with limited existing therapies. Oncology represents another major segment where RNA-based therapeutics, including siRNA and mRNA approaches, are used to target cancer cells, modulate tumor suppressor pathways, or enhance immune response against tumors. Infectious diseases are a growing segment driven by mRNA vaccines and RNA-based antivirals that provide rapid and effective responses to emerging pathogens. Neuromuscular disorders also represent an important indication where RNA therapies help correct genetic mutations or modulate protein expression to improve patient outcomes. Other indications include cardiovascular diseases, metabolic disorders, and autoimmune conditions where RNA-based therapies are being explored.

By End User
Hospitals and clinics represent a major end user segment as they administer RNA therapeutics and vaccines directly to patients, often in specialized treatment programs or clinical trial settings. Research institutes represent another significant segment where RNA technologies are studied for therapeutic development, disease modeling, and translational research. Pharmaceutical and biotech companies are key end users involved in the development, manufacturing, and commercialization of RNA-based therapeutics, driving innovation and bringing novel treatments to market.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a market research and consulting firm that provides end-to-end business solutions to organizations from research to consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology, ensuring that our clients receive tailored insights that address their specific business challenges and objectives.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.